Earnings digests and industry comparisons for Japan's biggest listed companies.
24 reports(page 1 of 2)
Otsuka said VOYXACT cut the two-year risk of kidney decline or failure by 97.1% in a 510-patient phase 3 trial. It completed a staged U.S. filing for full approval after accelerated approval in November 2025, and kept its 2026 forecast unchanged.
Ono has secured exclusive rights to develop IgG-degrading drugs in key Asian markets through a partnership with US-based Biohaven. The agreement involves an upfront payment of $80 million and aims to expand Ono's pipeline beyond oncology into autoimmune diseases.
Peptide Dream has reached a key milestone with US pharma giant MSD in its PCC program, validating the versatility of its PDPS platform. The undisclosed fee was already factored into forecasts for the year ending December 2026.
Otsuka completed its rolling submission for the biologics license application of IgA nephropathy drug VOYXACT in the US. While there is no immediate impact on fiscal 2026 earnings, this marks a key step toward long-term corporate value growth.
Rohto revised its fiscal year 2030 sales target up by 29 billion yen to 444 billion yen. The company is also adopting rolling forecasts instead of fixed targets through 2031.
Shionogi will acquire US biotech IntraBio for $2 billion, securing global rights to the rare disease drug AQNEURSA. This strategic move establishes a new high-value revenue pillar alongside its infectious disease business.
Otsuka Holdings subsidiary Daikochi Kogyo has started the New Drug Application process for its lung cancer drug Zeprelertinib in the United States. The company aims to complete the application by late 2026, leveraging an expedited review program to potentially accelerate market entry.
Rohto updated its long-term strategy on Oct. 2, targeting 4,640 billion yen in sales by fiscal year 2031 with a 12.9% operating margin. The pharma giant also committed to significantly increasing its dividend payout ratio to drive shareholder value.
Daiichi Sankyo confirmed an appeal by NTK regarding its acquisition of Fortis Healthcare. The defendant faces a massive Y203.3 billion damages claim despite winning the first-instance trial.
Chugai announced the discontinuation of its obesity candidate emagrobart due to efficacy limits. The biopharma is shifting focus to spinal muscular atrophy with zero financial impact on fiscal 2026.
Kobayashi confirmed receipt of an initial joint proposal from Japan Industrial Promotion Group (NSSK) and CVC Capital Partners for delisting. The company stated it has made no decision yet as negotiations remain in early stages.
Otsuka reported that its subunit Daio has achieved a significant progression-free survival extension in treating advanced non-small cell lung cancer. The phase 3 trial showed hazard ratios of 0.50, highlighting the potential for a new treatment standard.
